Ludovic Durrieu, PhD
Supervisor:Dr. David Waisman
Program of Study:Postdoctoral Fellow, Biochemistry & Molecular Biology
Project Title:Role of plasminogen receptor (S100A10) in tamoxifen resistance in breast cancer
Scholarships and/or Awards:
- Cancer Research Training Program (CRTP) Traineeship Award 2017
- 2014 BrightRed Graduate Research Award of Heart and Stroke foundation (sept 2014)
- Scholarship of Fondation CHU Ste-Justine/Fondation des Etoiles (sept 2010 – Aug 2013)
- Scholarship of department of Microbiology and Immunology (University of Montreal ; may 2009 – march 2011)
During my academic formation, I studied biology, and more specifically immunology. I worked in different laboratories, including Dr Henri-Jean Garchon’s laboratory (Paris, France), Dr Yves Rivière’s laboratory (Paris, France), Dr Saoussen Karray’s laboratory (Paris, France), and Elie Haddad’s laboratory (Montreal, Canada). During this time, I studied the implication of immunosuppressor cells in diabetes, T cell responses in hepatitis C virus infection, the implication of Fas expression in tumor growth, and the cytotoxic activity of cytokine-induced killer cells against leukemic cells. All those subjects were implicated in human health to better understand the relationship between the immune system and diseases, including autoimmune disease, viral infections and essentially cancer.
In addition, I have already published seven articles: three as first author, two as second author and two as co-authors. Among the seven articles, four are linked with cancer. My career goal is to obtain an academic position at the university and to supervise my own scientific team. To acquire my objective, I wish to improve my knowledge in the health domain, in particular in cancer and molecular biology. Thus, in my future projects, I could suggest different therapies, either at a cellular or molecular level or both, for different diseases, including cancer.
“Fas ligand deficiency impairs tumor immunity by promoting an accumulation of monocytic myeloid-derived suppressor cells” Peyvandi S, Buart S, Samah B, Vétizou M, Zhang Y, Durrieu L et al. October 2015, Cancer Research 75(20): 4292-301.
“Implication of different effector mechanisms by cord blood-derived and peripheral blood-derived cytokine-induced killer cells to kill precursor B acute lymphoblastic leukemia cell lines” Ludovic Durrieu et al. Jun 2014, Cytotherapy 16(6): 845-56.
“Cord blood-derived and peripheral blood-derived cytokine-induced killer cells are sensitive to fas-mediated apoptosis.” Ludovic Durrieu et al. September 2013, Biol Blood Marrow Transplant 19(9): 1407-11.
“Human IFN alpha increases the cytotoxic effect of Cord Blood-derived cytokine-induced killer (CIK) cells on human B- acute lymphoblastic leukemia cell lines.” Ludovic Durrieu et al. November 2012, Cytotherapy 14(10): 1245-57.
“Hepatitis C virus-specific cellular immune responses in individuals with no evidence of infection” Rivière Y, Montange T, Janvier G, Marnata C, Durrieu L et al. March 2012, Virology Journal 9:76.
“Description of new xenograft model of metastatic neuroblastoma using NOD/SCID/IL2rg null (NSG) mice” Hervé Sartelet, Ludovic Durrieu et al. January-February 2012, In Vivo 26(1): 19-30.
"Use of Immunoglobulins in the prevention of Graft versus Host Disease in a xenogenic NOD/scid gc- mouse model” Joëlle Gregoire-Gauthier, Ludovic Durrieu et al. March 2012, Bone Marrow Transplantation 47(3): 439-450.